Filtern
Volltext vorhanden
- ja (4)
Gehört zur Bibliographie
- ja (4)
Dokumenttyp
Sprache
- Englisch (4)
Schlagworte
- positron emission tomography (4)
- lymphoma (3)
- CXCR4 (2)
- chemokine receptor (2)
- in vivo imaging (2)
- CXCR4/SDF-1 (1)
- DLBCL (1)
- FDG PET/CT (1)
- FDG-PET (1)
- FLT-PET (1)
- NVP-BGT226 (1)
- [18F]Fluorodeoxythymidine (1)
- acute myeloid leukemia (1)
- autologous transplantation (1)
- bone disease (1)
- cancer (1)
- cells (1)
- early response (1)
- imaging proliferation (1)
- in-vivo (1)
- inhibition (1)
- involvement (1)
- malignancies (1)
- mammalian target of rapamycin (1)
- microenvironment (1)
- multiple myeloma (1)
- non-hodgkins-lymphoma (1)
- phosphatidylinositol-3-kinase (1)
- prognostic value (1)
- signaling pathway (1)
- survival (1)
- target (1)
- therapeutic target (1)
- tumor (1)
CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination andpoor prognosis. We evaluated the novel CXCR4 probe [\(^{68}\)Ga]Pentixafor for invivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [\(^{68}\)Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [\(^{68}\)Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [\(^{18}\)F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34\(^{+}\) flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [\(^{68}\)Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases.